You have full text access to this OnlineOpen article Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
Aibin Zhang, Yigang Qian, Zhou Ye, Haiyong Chen, Haiyang Xie, Lin Zhou, Yan Shen and Shusen Zheng
Version of Record online: 18 JAN 2017 | DOI: 10.1002/cam4.993
Pancreatic cancer-associated fibroblasts (CAFs) promote M2 polarization of macrophages by increasing ROS production. M-CSF secreted by CAF contribute to the enhanced ROS production and M2 polarization. CAF-induced M2 macrophages promote growth and migration of pancreatic tumor cells.
You have full text access to this OnlineOpen article Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration
Yingying Hu, Xiangwei Sun, Chenchen Mao, Gangqiang Guo, Sisi Ye, Jianfeng Xu, Ruanmin Zou, Jun Chen, Ledan Wang, Ping Duan and Xiangyang Xue
Version of Record online: 15 JAN 2017 | DOI: 10.1002/cam4.994
LncRNA TUG1 expression was significantly upregulated in cervical cancer and correlated with tumor size, international federation of gynecology and obstetrics (FIGO) stage, cell differentiation, and lymph node metastasis. Knockdown of TUG1 expression in cervical cancer cells inhibited cell proliferation and promoted cell apoptosis. Knockdown of TUG1 expression inhibited migration and invasion of cervical cancer cells via the mechanism of epithelial–mesenchymal transition (EMT).
You have full text access to this OnlineOpen article Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
Theresa A. Koleck, Catherine M. Bender, Susan M. Sereika, Christopher M. Ryan, Puja Ghotkar, Adam M. Brufsky, Rachel C. Jankowitz, Priscilla F. McAuliffe, Beth Z. Clark and Yvette P. Conley
Version of Record online: 13 JAN 2017 | DOI: 10.1002/cam4.964
Findings support the hypothesis that variation in pathologic features of breast tumors impact preadjuvant therapy cognitive performance in postmenopausal women with early-stage breast cancer. Certain features related to more aggressive tumor phenotypes or inferior prognosis were found to be implicated in poorer cognitive performance.
You have full text access to this OnlineOpen article BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma
Wei Gao, John Zeng-Hong Li, Si-Qi Chen, Chiao-Yun Chu, Jimmy Yu-Wai Chan and Thian-Sze Wong
Version of Record online: 13 JAN 2017 | DOI: 10.1002/cam4.982
Brain-expressed X-linked 3 (BEX3) was upregulated in head and neck cancers and NPC. (1) Circos plots showing meta-analysis of BEX family members in human malignancies using CancerMA. (2) Forest plot showing BEX3 expression in head and neck cancers. NGFRAP1: BEX3. (3) Expression level of BEX3 in NPC and normal tissues in GSE12452 from Oncomine. (4) Expression level of BEX3 in NPC and normal tissues in GSE12452 from Gene Expression Commons
You have full text access to this OnlineOpen article Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival
Olusola O. Faluyi, Lawson Eng, Xin Qiu, Jiahua Che, Qihuang Zhang, Dangxiao Cheng, Nanjiao Ying, Alvina Tse, Qin Kuang, Lorin Dodbiba, Daniel J. Renouf, Sharon Marsh, Sevtap Savas, Helen J. Mackay, Jennifer J. Knox, Gail E. Darling, Rebecca K. S. Wong, Wei Xu, Abul Kalam Azad and Geoffrey Liu
Version of Record online: 11 JAN 2017 | DOI: 10.1002/cam4.989
Here, we evaluate candidate miRNA pathway polymorphisms in esophageal adenocarcinoma prognosis and attempt to validate them in an independent cohort of esophageal adenocarcinoma patients. We identified three candidate polymorphisms GEMIN3
rs197412, hsa-mir-124-1 rs531564, and KIAA0423 rs1053667 which were found associated with overall survival in esophageal adenocarcinoma and which remained significantly associated with overall survival in a combined cohort of both our discovery and validation cohorts. Future larger studies are required to confirm/validate the prognostic value of these polymorphisms in esophageal adenocarcinoma. You have full text access to this OnlineOpen article A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
Po-Han Lin, Huei-Ying Li, Sheng-Chih Fan, Tzu-Hang Yuan, Ming Chen, Yu-Hua Hsu, Yu-Hsuan Yang, Long-Yuan Li, Su-Peng Yeh, Li-Yuan Bai, Yu-Min Liao, Chen-Yuan Lin, Ching-Yun Hsieh, Ching-Chan Lin, Che-Hung Lin, Ming-Yu Lien, Tzu-Ting Chen, Yen-Hsuan Ni and Chang-Fang Chiu
Version of Record online: 10 JAN 2017 | DOI: 10.1002/cam4.969
We comprehensively analyzed 260 genes by next-generation sequencing (NGS) in 112 patients with de novo acute myeloid leukemia (AML). Our result suggested that parallel sequencing using NGS was a good strategy to handle the testing of multiple genes and could provide a rapid and accurate risk classification system for the clinical management of AML patients.
You have full text access to this OnlineOpen article Alendronate-anchored PEGylation of ceria nanoparticles promotes human hepatoma cell proliferation via AKT/ERK signaling pathways
Heng Cheng, Zhong-Li Liao, Lin-Hong Ning, Hong-Yan Chen, Shan-Shan Wei, Xiao-Chao Yang and Hong Guo
Version of Record online: 10 JAN 2017 | DOI: 10.1002/cam4.949
Ceria nanoparticles (CNPs) were considered as therapeutic agents for treating a number of diseases, including cancer. In this study, we found that CNPs-AL- polyethylene glycol (PEG)600, a type of surface-modified CNP, could promote proliferation of hepatoma cells in a dose-dependent manner. These results may provide information that is important for using CNPs-AL-PEG600 as a therapeutic agent in clinical cancer treatments.
You have full text access to this OnlineOpen article Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2
Danhua Zhu, Ming Tu, Bo Zeng, Lin Cai, Weiming Zheng, Zhipeng Su and Zhengquan Yu
Version of Record online: 8 JAN 2017 | DOI: 10.1002/cam4.987
The overexpression of miR-497 is significantly correlated with temozolomide resistance in glioma cells by regulating mammalian target of rapamycin (mTOR)/Bcl-2, and miR-497 may be used as a new target for treatment of chemotherapy-resistant glioma.
You have full text access to this OnlineOpen article Overexpression of TNKS1BP1 in lung cancers and its involvement in homologous recombination pathway of DNA double-strand breaks
Wei Tan, Hua Guan, Lian-Hong Zou, Yu Wang, Xiao-Dan Liu, Wei-Qing Rang, Ping-Kun Zhou, Hua-Dong Pei and Cai-Gao Zhong
Version of Record online: 6 JAN 2017 | DOI: 10.1002/cam4.995
TNKS1BP1 is overexpressed in human lung adenocarcinoma (LAC) and correlated with the LAC patients’ survival. TNKS1BP1 presents a potential new biomarker for LAC. TNKS1BP1 regulates the genomic stability and cellular sensitivity to DNA damage agents in A549s, and is associated with its function in regulating HR repair of DNA double-strand breaks.
You have full text access to this OnlineOpen article Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping
Huseini H. Kagdi, Maria A. Demontis, Paul A. Fields, Juan Carlos Ramos, Charles R. M. Bangham and Graham P. Taylor
Version of Record online: 30 DEC 2016 | DOI: 10.1002/cam4.928
Adult T-cell leukemia/lymphoma (ATL) has a highly variable clinical course and better prognostic markers are urgently required. Our study has shown human T-lymphotropic virus type 1 (HTLV-1)-infected cells have a CD4
+ CCR4 + CD26 − immunophenotype. Within this population, CD7 − immunophenotype suggests a diagnosis of ATL, CCR7 + immunophenotype identifies aggressive ATL, while CCR7 − CD127 − immunophenotype identifies progressive indolent ATL. You have full text access to this OnlineOpen article A novel serum microRNA signature to screen esophageal squamous cell carcinoma
Zebo Huang, Lan Zhang, Danxia Zhu, Xia Shan, Xin Zhou, Lian-wen Qi, Lirong Wu, Jun Zhu, Wenfang Cheng, Huo Zhang, Yan Chen, Wei Zhu, Tongshan Wang and Ping Liu
Version of Record online: 30 DEC 2016 | DOI: 10.1002/cam4.973
Our study conducted the multistep detection of miRNAs, including serum, tissue, arterial serum, and exosomes. A novel serum microRNA signature including five miRNAs was identified to detect ESCC.
You have full text access to this OnlineOpen article TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4-phenylbutyrate treatment
Xuefang Jin, Nana Wu, Juji Dai, Qiuxia Li and XiaoQiang Xiao
Version of Record online: 29 DEC 2016 | DOI: 10.1002/cam4.977
Sodium butyrate and sodium phenylbutyrate induced A549 cell death and responses in different extent. TXNIP is a critical mediator of those differences, which can be greatly upregulated by sodium butyrate but slightly by sodium phenyl butyrate.
You have full text access to this OnlineOpen article FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
Jinhua Wang, Yali Xu, Li Li, Lin Wang, Ru Yao, Qiang Sun and Guanhua Du
Version of Record online: 28 DEC 2016 | DOI: 10.1002/cam4.990
There was significantly higher FOXC1 expression in estrogen receptor-negative (ER-) breast cancer than that in estrogen receptor-positive (ER+) breast cancer. FOXC1 regulates expression of ER
α You have full text access to this OnlineOpen article Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression
Terumasa Sowa, Toshi Menju, Toyofumi F. Chen-Yoshikawa, Koji Takahashi, Shigeto Nishikawa, Takao Nakanishi, Kei Shikuma, Hideki Motoyama, Kyoko Hijiya, Akihiro Aoyama, Toshihiko Sato, Makoto Sonobe, Hiroshi Harada and Hiroshi Date
Version of Record online: 28 DEC 2016 | DOI: 10.1002/cam4.991
Hypoxia-inducible factor 1 (HIF-1) and carbonic anhydrase IX (CAIX) affected the chemosensitivity of lung cancer cell line and prognosis of lung cancer patients after induction chemoradiotherapy. Inhibition of HIF-1 and CAIX might improve prognosis of lung cancer patients.
You have full text access to this OnlineOpen article Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies
Mashaal Dhir, Haroon A. Choudry, Matthew P. Holtzman, James F. Pingpank, Steven A. Ahrendt, Amer H. Zureikat, Melissa E. Hogg, David L. Bartlett, Herbert J. Zeh, Aatur D. Singhi and Nathan Bahary
Version of Record online: 28 DEC 2016 | DOI: 10.1002/cam4.992
Genomic profiling-guided therapy can lead to clinical benefit and improved progression-free survival in patients with advanced gastrointestinal (GI) malignancies. Attempting genomic profiling earlier in the course of treatment prior to functional decline may allow more patients to benefit from these therapies.
You have full text access to this OnlineOpen article A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance
Wenxian Wang, Zhengbo Song and Yiping Zhang
Version of Record online: 20 DEC 2016 | DOI: 10.1002/cam4.978
Our study demonstrates the feasibility and sensitivity of detecting epidermal growth factor receptor (EGFR) T790M status in plasma samples from NSCLC patients with acquired EGFR-TKI resistance. The ddPCR assay detecting in plasma ctDNA T790M may provide an alternative method in some situations. Patients with acquired T790M mutation at the time of progression have gradual progression compared to those without T790M mutation. And T790M-positive patients have better clinical outcomes to EGFR-TKIs than T790M-negative patients.
You have full text access to this OnlineOpen article Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
Jorge D. Ramos, Martin F. Casey, Simon J. Crabb, Aristotelis Bamias, Lauren C. Harshman, Yu-Ning Wong, Joaquim Bellmunt, Ugo De Giorgi, Sylvain Ladoire, Thomas Powles, Sumanta K. Pal, Guenter Niegisch, Federica Recine, Ajjai Alva, Neeraj Agarwal, Andrea Necchi, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Matthew D. Galsky, Evan Y. Yu and RISC Investigators
Version of Record online: 20 DEC 2016 | DOI: 10.1002/cam4.986
Venous thromboembolism is common and has a negative impact on survival in patients with metastatic urothelial tract cancers. Non-urothelial histology, renal dysfunction, and the presence of cardiovascular disease or risk factors for cardiovascular disease increase a patient's risk for venous thromboembolism; however, there is no statistical difference in thrombotic risk between chemotherapy regimens.
You have full text access to this OnlineOpen article Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
Li Yan Lim, Hui Miao, Joline S. J. Lim, Soo Chin Lee, Nirmala Bhoo-Pathy, Cheng Har Yip, Nur Aishah B. M. Taib, Patrick Chan, Ern Yu Tan, Swee Ho Lim, Geok Hoon Lim, Evan Woo, Yia Swam Tan, Jung Ah Lee, Mabel Wong, Puay Hoon Tan, Kong Wee Ong, Fuh Yong Wong, Yoon Sim Yap and Mikael Hartman
Version of Record online: 20 DEC 2016 | DOI: 10.1002/cam4.985
Most existing evidence on response to neoadjuvant chemotherapy are from western countries, where tumor characteristics are different from Asia. This study is one of the largest studies done in Asia to determine the demographic of breast cancer patients who underwent neoadjuvant chemotherapy, clinicopathologic predictors for response to treatment, their long-term survival in an actual clinical practice setting, and the prognostic value of pathological complete response on overall survival in Asia.
You have full text access to this OnlineOpen article Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18–25 years: event-triggered analysis of a randomized controlled trial
Feng-cai Zhu, Shang-Ying Hu, Ying Hong, Yue-Mei Hu, Xun Zhang, Yi-Ju Zhang, Qin-Jing Pan, Wen-Hua Zhang, Fang-Hui Zhao, Cheng-Fu Zhang, Xiaoping Yang, Jia-Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan-Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi and Frank Struyf
Version of Record online: 20 DEC 2016 | DOI: 10.1002/cam4.869
This is the first long-term, large-scale, randomized clinical trial of human papillomavirus (HPV) vaccination in China, where cervical cancer is a major concern. With a mean follow-up of approximately 57 months post-dose 1, the HPV-16/18 AS04-adjuvanted vaccine was efficacious against HPV-16/18-associated cervical intraepithelial neoplasia and infection, immunogenic, and had a clinically acceptable safety profile in young Chinese women. Prophylactic HPV vaccination and screening could potentially reduce the high HPV epidemic and cervical cancer burden in China.
You have full text access to this OnlineOpen article Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women
Xia Li, Hailiang Huang, Yanfang Guan, Yuhua Gong, Cheng-Yi He, Xin Yi, Ming Qi and Zhi-Ying Chen
Version of Record online: 20 DEC 2016 | DOI: 10.1002/cam4.953
To search for the optimal therapeutic targets, we investigated the hierarchy structure of the somatic mutations of 23 early cervical cancers of Chinese women using whole-exome sequencing approach. We found that individual cancer displayed a unique phylogenetic tree and “cancer neo-epitope tree” comprising different set of subpopulations, genetic mutations and associated neo-epitopes, which are predicted according to their strong binding with major histocompatibility complex class I molecules (MHC-I). Conceivably, the neo-epitopes at the top of the tree were the optimal immunotherapeutic targets, possessing the potential to mediate T-cell killing of the descendant cells.
You have full text access to this OnlineOpen article Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer
Eric T. Miller, Karim Chamie, Lorna Kwan, Michael S. Lewis, Beatrice S. Knudsen and Isla P. Garraway
Version of Record online: 20 DEC 2016 | DOI: 10.1002/cam4.981
Men with high-grade prostate cancer (HGPC) are at a greatest risk of disease progression. Clinical risk factors associated with castration-resistant prostate cancer (CRPC), metastases, and prostate cancer-specific mortality (PCSM) were identified in a contemporary HGPC cohort. Men with these risk factors may benefit from combinatorial therapies that include definitive treatment of the primary tumor.
You have full text access to this OnlineOpen article microRNA from brush biopsy to characterize oral squamous cell carcinoma epithelium
Yalu Zhou, Antonia Kolokythas, Joel L. Schwartz, Joel B. Epstein and Guy R. Adami
Version of Record online: 18 DEC 2016 | DOI: 10.1002/cam4.951
This study sought to identify tumor epithelial miRNA expression changes in oral squamous cell carcinoma to determine if these changes could be used to identify the disease noninvasively. By focusing on pure epithelium miRNA, acquired rapidly and simply with brush biopsy, we showed the potential to diagnose this disease with miRNA from epithelium. And we use a simple variation of standard pathway identification methods to minimize false positives and identify the neurotrophin signaling pathway as a target of these miRNAs.
You have full text access to this OnlineOpen article Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma
Jin-Hua Chen, Yu-Chun Yen, Tsung-Ming Chen, Kevin Sheng-Po Yuan, Fei-Peng Lee, Kuan-Chou Lin, Ming-Tang Lai, Chia-Che Wu, Chia-Lun Chang and Szu-Yuan Wu
Version of Record online: 17 DEC 2016 | DOI: 10.1002/cam4.976
Metachronous second primary head and neck squamous cell carcinoma are rare and optimal therapeutic decisions for metachronous second primary head and neck squamous cell carcinomas (HNSCCs) are unclear. Suitable treatments and prognostic factors for the population were analyzed. This study is the first to estimate the prognostic factors of metachronous second primary HNSCCs.
You have full text access to this OnlineOpen article Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Francine Foss, Barbara Pro, H. Miles Prince, Lubomir Sokol, Dolores Caballero, Steven Horwitz and Bertrand Coiffier
Version of Record online: 16 DEC 2016 | DOI: 10.1002/cam4.939
Patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) typically have a poor prognosis. Responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class 1 histone deacetylase inhibitor approved by the US FDA for the treatment of PTCL in patients who have received ≥1 prior therapies. The analysis presented here demonstrated that romidepsin had similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy, thereby supporting the use of romidepsin for patients with relapsed or refractory PTCL regardless of the number of prior therapies.
You have full text access to this OnlineOpen article Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma
Shingo Akiyama, Hiroshi Saeki, Yuichiro Nakashima, Makoto Iimori, Hiroyuki Kitao, Eiji Oki, Yoshinao Oda, Yusaku Nakabeppu, Yoshihiro Kakeji and Yoshihiko Maehara
Version of Record online: 5 DEC 2016 | DOI: 10.1002/cam4.979
MTH1 is a pyrophosphatase that hydrolyzes oxidized dNTPs in dNTP pool. This is the first study to show a correlation between MTH1 expression and malignancy of esophageal squamous cell carcinoma (ESCC). The enhanced MTH1 expression strongly correlates with tumor progression and is an independent prognostic factor in ESCC.
You have full text access to this OnlineOpen article Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
Jihyun Kwon, Chang-Ki Min, Kihyun Kim, Jae-joon Han, Joon Ho Moon, Hye Jin Kang, Hyeon-Seok Eom, Min Kyoung Kim, Hyo Jung Kim, Dok Hyun Yoon, Jeong-Ok Lee, Won Sik Lee, Jae Hoon Lee, Je-Jung Lee, Yoon-seok Choi, Sung hyun Kim and Sung-soo Yoon
Version of Record online: 1 DEC 2016 | DOI: 10.1002/cam4.970
We found that the combination chemotherapy of thalidomide, steroid, and alkylating agent was very effective for relapsed or refractory multiple myeloma patients even after previous treatment with novel agents. The risk of infection was higher in cyclophosphamide-combined regimen than melphalan.
You have full text access to this OnlineOpen article High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation
Soichiro Sakamoto, Hiroshi Kawabata, Junya Kanda, Tatsuki Uchiyama, Chisaki Mizumoto, Toshiyuki Kitano, Tadakazu Kondo, Masakatsu Hishizawa, Naohisa Tomosugi and Akifumi Takaori-Kondo
Version of Record online: 1 DEC 2016 | DOI: 10.1002/cam4.974
We previously showed that patients with hematologic malignancies exhibit dynamic changes in levels of hepcidin-25, which is the key regulator of systemic iron, during allogeneic haematopoietic stem cell transplantation. In this study, we investigated the association of pre-transplant serum hepcidin-25 levels with overall survival, and found that the patients with high levels of pre-transplant hepcidin-25 had significantly lower overall survival than patients with low-hepcidin-25. Moreover, the incidence of platelet engraftment was significantly lower in patients with high pre-transplant hepcidin-25.
You have full text access to this OnlineOpen article Muscle RAS oncogene homolog ( MRAS) recurrent mutation in Borrmann type IV gastric cancer
Makiko Yasumoto, Etsuko Sakamoto, Sachiko Ogasawara, Taro Isobe, Junya Kizaki, Akiko Sumi, Hironori Kusano, Jun Akiba, Takuji Torimura, Yoshito Akagi, Hiraku Itadani, Tsutomu Kobayashi, Shinichi Hasako, Masafumi Kumazaki, Shinji Mizuarai, Shinji Oie and Hirohisa Yano
Version of Record online: 28 NOV 2016 | DOI: 10.1002/cam4.959
This is the first report of the genomic profile of Borrmann type IV gastric cancer. We found that muscle RAS oncogene homolog (
MRAS) is recurrently mutated in Borrmann type IV gastric cancer. We also detected IGF1R gene amplification and that it was correlated with high levels of mRNA and protein expression. You have full text access to this OnlineOpen article GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome
Jing-Dong Zhou, Jiang Lin, Ting-Juan Zhang, Ji-Chun Ma, Lei Yang, Xiang-Mei Wen, Hong Guo, Jing Yang, Zhao-Qun Deng and Jun Qian
Version of Record online: 28 NOV 2016 | DOI: 10.1002/cam4.984
GPX3 methylation was identified in 15% myelodysplastic syndrome (MDS) patients, and was associated with adverse prognosis. GPX3 methylation density was significantly increased during the progression from MDS to sAML in follow-up patients.
You have full text access to this OnlineOpen article DLL4 overexpression increases gastric cancer stem/progenitor cell self-renewal ability and correlates with poor clinical outcome via Notch-1 signaling pathway activation
Zhi-Feng Miao, Hao Xu, Hui-Mian Xu, Zhen-Ning Wang, Ting-Ting Zhao, Yong-Xi Song and Ying-Ying Xu
Version of Record online: 28 NOV 2016 | DOI: 10.1002/cam4.962
DLL4 expression is associated with TNM stage and cancer metastasis, with high amounts of DLL4 leading to poor outcome. DLL4 silencing inhibited the self-renewal ability of GCSPCs and increased their multidifferentiation capacity, resulting in reduced GCSPC ratios. DLL4 knockdown also blocked the Notch-1 pathway, weakening invasion ability, and resistance to 5-FU chemotherapy.
You have full text access to this OnlineOpen article Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database
Neomi Vin-Raviv, Tomi Akinyemiju, Qingrui Meng, Swati Sakhuja and Reid Hayward
Version of Record online: 28 NOV 2016 | DOI: 10.1002/cam4.968
In view of the rapidly increased use of marijuana in the general population. There is significant interest in examining the health effects of marijuana use among adults in general, but more importantly among those with health conditions or chronic diseases. In this study we examined the relationships between marijuana use and health outcomes among hospitalized patients, including hospitalized patients with and without a diagnosis of cancer.
You have full text access to this OnlineOpen article Does radiotherapy still have a role in unresected biliary tract cancer?
Erqi L. Pollom, Muthuraman Alagappan, Lesley S. Park, Alice S. Whittemore, Albert C. Koong and Daniel T. Chang
Version of Record online: 28 NOV 2016 | DOI: 10.1002/cam4.975
The benefits of radiotherapy for elderly patients with inoperable biliary tract cancer remain unclear due to the lack of randomized data given the rarity of this cancer. Using the SEER-Medicare database, we found that the use of radiotherapy has declined over time, and is influenced by tumor, patient, and socioeconomic factors, and that any survival benefit with radiotherapy is confined to those patients who received concurrent chemotherapy.
You have full text access to this OnlineOpen article Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma
Andreas Müller, Alina Jurcoane, Sied Kebir, Philip Ditter, Felix Schrader, Ulrich Herrlinger, Theophilos Tzaridis, Burkhard Mädler, Hans H. Schild, Martin Glas and Elke Hattingen
Version of Record online: 28 NOV 2016 | DOI: 10.1002/cam4.966
Quantitative T1 subtraction maps uncover a cloudy-enhancing compartment that is not detected in conventional MRI and has prognostic value for patients with glioblastoma.
You have full text access to this OnlineOpen article The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis
Ziran Zhao, Pan Wang, Yibo Gao and Jie He
Version of Record online: 23 NOV 2016 | DOI: 10.1002/cam4.945
This is the first dedicated systematic review and meta-analysis regarding the independent prognostic value of p53 in patients with esophageal squamous-cell carcinoma. We identified a statistically significant negative impact of p53 high expression, instead of TP53 mutations, on overall survival of esophageal squamous-cell carcinoma (ESCC) patients.
You have full text access to this OnlineOpen article General practice consultations, diagnostic investigations, and prescriptions in the year preceding a lung cancer diagnosis
Louise M. Guldbrandt, Henrik Møller, Erik Jakobsen and Peter Vedsted
Version of Record online: 23 NOV 2016 | DOI: 10.1002/cam4.965
General practice consultations, diagnostic investigations, and prescriptions in the year preceding a lung cancer diagnosis.
You have full text access to this OnlineOpen article Migration of breast cancer cell lines in response to pulmonary laminin 332
Philip M. Carpenter, Priyanka Sivadas, Spencer S. Hua, Cally Xiao, Alyssa B. Gutierrez, Tuan Ngo and Paul D. Gershon
Version of Record online: 22 NOV 2016 | DOI: 10.1002/cam4.957
This study demonstrates that laminin 332 in lung epithelium has the potential to induce tumor migration, which in turn is a requirement for metastasis. This investigation provides evidence that the tumor promoting potential of laminin 332 in lung may originate in the microenvironment rather than in tumor cells alone. The findings raise the possibility that laminin 332 plays a role in pulmonary breast carcinoma metastases and that it may provide a target for antimetastasis therapy.
You have full text access to this OnlineOpen article Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients
Rouslan Kotchetkov, Esther Masih-Khan, Chia-Min Chu, Eshetu G. Atenafu, Christine Chen, Vishal Kukreti, Suzanne Trudel, Rodger Tiedemann and Donna E. Reece
Version of Record online: 18 NOV 2016 | DOI: 10.1002/cam4.799
The cumulative incidence of secondary primary malignancies in our patients with relapsed/refractory multiple myeloma receiving Len-dex was 1.54% from diagnosis and 5.24% from initiation of lenalidomide. Older patients who received more Len-dex therapy and were on G-CSF support were at higher risk for secondary primary malignancy.
You have full text access to this OnlineOpen article Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation
Minzhi Xing and Hyun S. Kim
Version of Record online: 16 NOV 2016 | DOI: 10.1002/cam4.936
Overall Survival from OLT by Region LRT status and Waitlist Time. Mean survival was 124.9 months in HWT, High LRT regions; 114.6 months in LWT, High LRT regions; 116.0 in HWT, Low LRT regions; and 114.8 months in LWT, Low LRT regions,
P = 0.0006. You have full text access to this OnlineOpen article An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study
Xiao-Hui Li, Hui Chang, Bing-Qing Xu, Ya-Lan Tao, Jin Gao, Chen Chen, Chen Qu, Shu Zhou, Song-Ran Liu, Xiao-Hui Wang, Wen-Wen Zhang, Xin Yang, Si-Lang Zhou and Yun-Fei Xia
Version of Record online: 10 NOV 2016 | DOI: 10.1002/cam4.947
Pretreatment Glasgow prognostic score (GPS), NLR, platelet-lymphocyte ratio (PLR), LMR of 388 nasopharyngeal carcinoma (NPC) patients who were recruited prospectively in the 863 Program No. 2006AA02Z4B4 were assessed. After multivariate analysis of the 249 patients of the development set, age, T stage, N stage, and GPS, NLR, LMR appeared to be independent prognostic factors of 5-year disease-specific survival (DSS), and a nomogram was established to predict the DSS based on these factors. The model was validated in 139 patients of the validation set.
You have full text access to this OnlineOpen article Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer
Yizhuo Wang, Chang Wang, Huijie Xiao, Chao Niu, Haitao Wu, Haofan Jin, Cheng Yao, Hua He, Huimin Tian, Fujun Han, Dan Li, Wei Han, Jianting Xu, Jingtao Chen, Jiuwei Cui and Wei Li
Version of Record online: 27 OCT 2016 | DOI: 10.1002/cam4.942
The adjuvant treatment combining chemotherapy with cellular immunotherapy is well tolerated and significantly improves the clinical outcome of patients with stage II/III gastric cancer (GC), when compared with chemotherapy alone, therefore warrants further attention in treatment for relapsed GC after tumor resection.